Omnicell マネジメント
マネジメント 基準チェック /34
Omnicellの CEO はRandy Lippsで、 Sep1992年に任命され、 の在任期間は 33.58年です。 の年間総報酬は$ 7.53Mで、 11.2%給与と88.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.98%を直接所有しており、その価値は$ 38.77M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と6.9年です。
主要情報
Randy Lipps
最高経営責任者
US$7.5m
報酬総額
| CEO給与比率 | 11.24% |
| CEO在任期間 | 33.6yrs |
| CEOの所有権 | 2.0% |
| 経営陣の平均在職期間 | 3.2yrs |
| 取締役会の平均在任期間 | 6.9yrs |
経営陣の近況
Recent updates
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
Feb 12
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Nov 13OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Omnicell Q2 Earnings: Market Ignoring The Segments
Jul 31Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
Jul 16Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 28Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
May 14US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
May 09Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Apr 07Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Mar 20Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Feb 14Omnicell Q4 Earnings: Ignore The Short-Term Noise
Feb 12Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 28Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
Nov 27Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Nov 02Omnicell Q3 Earnings: Look At The Growth Segment
Nov 01Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Oct 31Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$20m |
| Dec 31 2025 | US$8m | US$847k | US$2m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$23m |
| Mar 31 2025 | n/a | n/a | US$21m |
| Dec 31 2024 | US$8m | US$822k | US$13m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$21m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$11m | US$813k | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$8m | US$804k | US$6m |
| Sep 30 2022 | n/a | n/a | US$48m |
| Jun 30 2022 | n/a | n/a | US$61m |
| Mar 31 2022 | n/a | n/a | US$72m |
| Dec 31 2021 | US$8m | US$768k | US$78m |
| Sep 30 2021 | n/a | n/a | US$80m |
| Jun 30 2021 | n/a | n/a | US$60m |
| Mar 31 2021 | n/a | n/a | US$35m |
| Dec 31 2020 | US$8m | US$721k | US$32m |
| Sep 30 2020 | n/a | n/a | US$38m |
| Jun 30 2020 | n/a | n/a | US$49m |
| Mar 31 2020 | n/a | n/a | US$69m |
| Dec 31 2019 | US$7m | US$711k | US$61m |
報酬と市場: Randyの 総報酬 ($USD 7.53M ) は、 US市場 ($USD 5.48M ) の同規模の企業の平均を上回っています。
報酬と収益: Randyの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Randy Lipps (68 yo)
33.6yrs
在職期間
US$7,531,852
報酬
Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps has been Executive Chairman of Omnic...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 33.6yrs | US$7.53m | 1.98% $ 38.8m | |
| Executive VP & CFO | less than a year | US$1.51m | データなし | |
| Executive VP & COO | 1.5yrs | US$4.01m | 0.029% $ 559.4k | |
| Executive VP | 5yrs | US$2.46m | 0.023% $ 448.5k | |
| VP, Chief Accounting Officer & Corporate Controller | 2.1yrs | データなし | 0.0086% $ 168.2k | |
| Senior VP & CTO | 1.1yrs | データなし | データなし | |
| Senior VP & Chief Corporate Development Officer | no data | データなし | データなし | |
| Senior VP & Chief Marketing Officer | no data | データなし | データなし | |
| SVP & Chief People Officer | less than a year | データなし | データなし | |
| Senior VP & GM of International | 4.3yrs | データなし | データなし | |
| Senior Vice President of Quality & Product Regulatory | 4.3yrs | データなし | データなし | |
| Chief of Staff | 8.8yrs | データなし | データなし |
3.2yrs
平均在職期間
51.5yo
平均年齢
経験豊富な経営陣: OMCLの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 33.6yrs | US$7.53m | 1.98% $ 38.8m | |
| Independent Director | 2.3yrs | US$318.51k | 0.033% $ 656.2k | |
| Independent Director | 13.3yrs | US$322.37k | 0.14% $ 2.8m | |
| Independent Director | 7.1yrs | US$323.62k | 0.10% $ 2.0m | |
| Lead Independent Director | 12.3yrs | US$355.14k | 0.099% $ 1.9m | |
| Independent Director | 4.8yrs | US$303.23k | 0.040% $ 775.2k | |
| Independent Director | 6.9yrs | US$325.65k | 0.051% $ 990.2k | |
| Independent Director | 3.9yrs | US$330.14k | 0.038% $ 740.3k | |
| Independent Director | 2.8yrs | US$298.15k | 0.032% $ 625.9k |
6.9yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: OMCLの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/30 18:25 |
| 終値 | 2026/04/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Omnicell, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20
| アナリスト | 機関 |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |